Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hong Kong firm petitions FDA on acetaminophen equivalency

This article was originally published in The Tan Sheet

Executive Summary

Wishing to bring its "effective, safe but cheap drug to U.S. patients," Bright Future Pharmaceutical Lab Ltd. asks FDA to allow the use of GlaxoSmithKline's 500-mg acetaminophen drug Panadol as the reference listed drug in an abbreviated new drug application for the Hong Kong firm's BF-PARADAC. Although the Orange Book contains no RLD identical to BF-PARADAC in dosage form, strength or formulation, Panadol is pharmaceutically and/or therapeutically equivalent to Bright Future's drug, the company says in its ANDA suitability 1petition dated Dec. 17. Bright Future says the bioequivalence study of BF-PARADAC using Panadol as the reference is complete, and asks FDA to suggest another RLD equivalent to its drug

You may also be interested in...

Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.

In Case You Missed It … News On China Patents, EMA Chief, And More

We clean out your Martin Luther King Day inbox so you don't have to.

At Muted J.P. Morgan, Focus Is Execution, But US Pricing Is Persistent Overhang

Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts